TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive Aflibercept Improves Overall Survival In Second-Line Colorectal Cancer Setting April 29, 2011